Some anaesthetic agents are known to inhibit microbial growth. The aim of this in vitro study was to investigate possible antimicrobial effects of two frequently used agents in intensive care units, dexmedetomidine and midazolam. Antimicrobial effect was tested on Staphylococcus aureus, Enterococcus faecalis, Escherichia coli and Pseudomonas aeruginosa by broth microdilution method. Midazolam showed inhibitor and bactericidal effect on S. aureus at concentrations 256 µg.ml -1 and 512 µg.ml -1 respectively and on E. faecalis at concentrations 128 µg.ml -1 and 256 µg.ml -1 . Dexmedetomidine demonstrated inhibitor effect on S. aureus, E. coli and P. aeruginosa at concentrations 32 µg.ml -1 , 16 µg.ml -1 and 16 µg.ml -1 respectively. Midazolam had inhibitor and bactericidal effects on S. aureus and E. faecalis. Dexmedetomidine had only inhibitor effects on S. aureus, E. coli and P. aeruginosa. Further studies are needed to determine the antimicrobial mechanisms and clinical applications.
Various intravenous anaesthetic agents are used for sedation via venous catheters by continuous infusion in the intensive care unit. Some anaesthetic agents and sedatives are known to support the growth of micro-organisms or to cause immunsupression [1] [2] [3] . There are also published reports of systemic bacteraemias and wound infections related to the use of various anaesthetic agents 4 . However, in several papers, anaesthetic agents have been reported to inhibit and others not to support microbial growth [1] [2] [3] [4] . These properties may be advantageous for the infections based on contamination. Midazolam is a benzodiazepine often used in intensive care for sedation. It has been previously reported to have antimicrobial properties which were supposed to be related to the preservative it contained and its pH value of 3.0 5 . Dexmedetomidine, a highly selective alpha 2-receptor agonist, has also become a frequently used infusion drug for sedation in intensive care. It is water-soluble with a pH value of 4.5 to 7.0 and preservative-free 6 . The aim of this study was to evaluate the antimicrobial effects of dexmedetomidine and midazolam on microorganisms highly encountered in hospital settings.
METHODS
This study was performed at the Clinical Microbiology Laboratory of the Medical School of Karaelmas University, Zonguldak, Turkey in 2006. Approval for the study was given by the local ethics committee of the Medical School of Karaelmas University. Antibacterial activities of dexmedetomidine and midazolam were investigated by broth microdilution method according to the Clinical and Laboratory Standards Institute standard procedures 7, 8 . Briefly, midazolam (Roche, Fontenay-sous-Bois, France, supplied in a 3 ml ampoule containing 5 mg.ml -1 in sodium chloride solution) was diluted with cation-adjusted Mueller-Hinton broth (CAMHB) to the final concentrations of 512 µg.ml -1 , 256 µg.ml -1 , 128 µg.ml -1 , 64 µg.ml -1 , 32 µg.ml -1 , 16 µg.ml -1 , 8 µg.ml -1 , 4 µg.ml -1 , 2 µg.ml -1 , 1 µg.ml -1 and 0.5 µg.ml -1 . Dexmedetomidine hydrochloride (Abbott, Rocky Mount, nC, USA, supplied in a 2 ml ampoule containing 100 µg.ml -1 in sodium chloride solution) was diluted with CAMHB to the final concentrations of 32 µg.ml -1 , 16 µg.ml -1 , 8 µg.ml -1 , 4 µg.ml -1 , 2 µg.ml -1 , 1 µg.ml -1 , 0.5 µg.ml -1 and 0.25 µg.ml -1 . In order to prepare the broth microdilution panels, 0.1 ml of broth containing each anaesthetic concentration mentioned above were dispensed to the sterile wells on microdilution trays. Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as the control micro-organisms. Standard inoculums of the actively growing test micro-organisms were prepared with sterile saline by adjusting the turbidity of cultures to the 0.5
McFarland standard (contains 1 to 2×10 8 CFU.ml -1 [colony-forming units per mililitre] bacteria). These suspensions were diluted 1:10 in broth to 10 7 CFU.ml -1 bacterial concentration. Each well of the prepared microdilution tray was inoculated with 5 µl of the prepared 10 7 CFU.ml -1 bacteria suspensions. Bacteria in 5×10 5 CFU.ml -1 final concentration, in total volume of 0.1 ml of CAMHB including the anaesthetic agents in the defined concentrations were incubated at 35°C for 20 hours. Growth and sterility control wells on the trays were used. Minimal inhibitory concentrations (MIC) were accepted as the lowest concentration of the agent which inhibited visible growth of the bacterium. Haze or turbidity in the wells indicated growth. Minimal bactericidal concentrations were also examined according to standard procedures 9, 10 .
Briefly, after determination of MICs following incubation, quantitative subcultures were performed with samples from each well with concentrations at and above the MIC of the tested agent. The subculture aliquots were streaked on the entire surface of blood agar plates and incubated for 48 hours. After incubation any visible colonies were counted on each subculture plate. Colony counts were also performed on the positive control well at the initial inoculation of the MIC test. Minimal bactericidal concentration was defined as the reduction of the initial inoculum by ≥99.9%. The pH values of all anaesthetic solutions were determined with a pH meter (Mettler MP 220, Toledo, Switzerland).
RESUlTS
In this study, midazolam showed inhibitor and bactericidal effects on S. aureus and E. faecalis at the concentrations listed in the Table 1 , but did not show any antimicrobial effect on E. coli and P. aeruginosa in these concentrations. Dexmedetomidine showed an inhibitor effect on S. aureus, E. coli and P. aeruginosa at the different concentrations (Table 1) . However, dexmedetomidine did not show any bactericidal effect on any strains tested. The pH values of tested dilutions of midazolam were 7.20 at 512 µg.ml -1 , 7.26 at 256 µg.ml -1 , 7.29 at 128 µg.ml -1 , 7.30 at 64 µg.ml -1 , 7.31 at 32 to 0.5 µg.ml -1 and dexmedetomidine were 7.27 at 32 µg.ml -1 , 7.29 at 16 to 4 µg.ml -1 , 7.30 at 2 to 0.5 µg.ml -1 .
DISCUSSIon
In this study we found that midazolam has antimicrobial properties on some micro-organisms, which is in accordance with previous studies. Midazolam had inhibitor and bactericidal effect on both S. aureus and E. faecalis. The concentration of 512 µg.ml -1 was effective on both bacteria. Dexmedetomidine had only inhibitor effect on S. aureus, E. coli and P. aeruginosa at the concentration of 32 µg.ml -1 .
Antimicrobial effects of various anaesthetic agents have been investigated in previous studies but the antibacterial mechanisms are not clear yet. Several studies established that the antimicrobial effects of some anaesthetics may depend on their molecular weight, pH and thermodynamic activity [11] [12] [13] . Some others showed an interaction between the cytoplasmic membrane and macromolecule 14, 15 .
It is possible for anaesthetic agents to be contaminated by micro-organisms during the preparation for infusion. There are also published reports of systemic bacteraemias and wound infections with S. aureus linked to the use of intravenous propofol 4 . The bactericidal property of thiopentone is thought to be related to its high pH (10.55) 12 . Most pathogenic bacteria prefer a narrow pH range of 6 to 8 13, 16 . Gudmundsson and colleagues reported that the growth of S. aureus (ATCC 25923), 17 . In some studies the pH range of midazolam was thought to be responsible for the inhibitor effect 18, 19 . On the other hand, in another study it is concluded that the antimicrobial effect of midazolam was due to the fact that it included HCl as a preservative 5 . Before dilution, the pH of midazolam is 3.0 and dexmedetomidine is 4.5 to 7. The pH of diluted drugs in our study had a narrow range of 7.2 to 7.31 after dilution. For this reason, the bactericidal properties of study agents could not be related to their pH in our study. Keles et al showed that midazolam had an antimicrobial effect on E. coli, P. aeruginosa, A. baumannii and E. coli ESBL, but dexmedetomidine had no antimicrobial effect on these tested micro-organisms 5 . It is noteworthy that in this study, midazolam was tested in the concentration of 5000 µg.ml -1 and dexmedetomidine in the concentration of 50 µg.ml -1 . Although these concentrations are higher than we used, broth was not included during the incubation of the microorganisms exposed to the drugs tested for 30 to 240 minutes.
Durak et al reported that midazolam demonstrated an inhibitor effect on the strains of S. aureus and E. faecalis only at the concentration of 0.225 mg.ml -1 20 . In clinical practice, these drugs are used in very diluted forms in the intensive care unit, so we would expect more dramatic results if we tested the drugs in higher concentrations. Higher concentrations of the drugs tested were limited according to the standard test procedure that certain ratios of broth and diluted drug be used in the wells during the incubation.
Lipid-based emulsions and preservative-free forms have been shown to support various micro-organisms by inhibiting the reticuloendothelial system and thereby suppressing the host's natural immunity 1, 21 .
Midazolam and dexmedetomidine are advantageous as they do not contain lipid emulsions. Dexmedetomidine and midazolam are also reported to inhibit immune function and inhibit the inflammatory response 22, 23 .
Although these agents have been shown to have antibacterial effects, these effects are concentrationdependent. While the dilution of these drugs in systemic usage may not have a systemic antibacterial effect, their antimicrobial effects in these concentrations may be advantageous for the inhibition of contamination during the preparation of the infusion solutions. For sedative effects, a plasma midazolam concentration 40 to 80 ng.ml -1 is needed 24 . On the other hand, plateau plasma midazolam levels of 600 µg.ml -1 are required for deep hypnotic effect 25 . This level of midazolam is also concordant with the concentration in our study which showed antibacterial effect in vitro. This suggests that midazolam might exert an antimicrobial effect in vivo.
Dexmedetomidine is generally initiated with a loading infusion of 1 µg.kg -1 over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 µg.kg -1 .h -1 (target concentration of 0.3 ng.ml -1 to 1.25 ng.ml -1 ) according to the instructions in the package insert. To prepare an infusion solution targeting these infusion rates, the drug is diluted in a final concentration 4 µg.ml -1 26 . In this study higher concentrations of dexmedetomidine (32 µg.ml -1 ) was shown to have in vitro antibacterial effect. According to our results we might recommend preparing the solution at a concentration higher than 32 µg.ml -1 adjusting the flow rate of the infusion. These modifications would be useful for avoiding the contamination of the solutions used for sedation. The possible benefit of these agents by reducing infections remains to be demonstrated in in vivo clinical trails.
In conclusion, midazolam and dexmedetomidine are shown to have in vitro antibacterial effects on some micro-organisms frequently encountered in hospital settings. Further studies are needed to determine the antimicrobial mechanisms and clinical applications.
